SRP-4053: Phase III planned

Sarepta amended its planned double-blind, placebo-controlled Phase III ESSENCE trial to evaluate 30 mg/kg IV SRP-4045 once weekly in patients with deletion mutations amenable to exon 45 skipping and 30 mg/kg IV SRP-4053 once weekly in patients with deletion mutations amenable to

Read the full 424 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE